Integrated Filing- Financial

Aarti Pharmalabs has announced a board meeting to review and approve the financial results for the quarter and nine months ended December 31, 2024. Key figures include standalone revenue from operations of ₹70.72 crore, total income of ₹73.78 crore, and a profit for the period of ₹7.35 crore.

The board has also declared an interim dividend of ₹2.50 per equity share.

This robust performance indicates strong operational health, potentially boosting investor confidence, while the dividend could enhance shareholder value, reflecting the company's solid financial position.